Skip to main content

Site notifications

GAZYVA Roche Products Pty Ltd

Product name
GAZYVA
Accepted date
Apr-2025
Active ingredients
obinutuzumab
Proposed indication
Gazyva (obinutuzumab) is used to treat adult patients with active lupus nephritis who are receiving standard therapy. Lupus nephritis occurs when the immune system mistakenly attacks the kidneys, causing inflammation which may damage the kidneys.
Application type
C (new indication)
Publication date
Apr-2025